May 17, 2017
Nicox welcomes new Board member
Nicox, the international ophthalmic R&D company, appointed Lauren P. Silvernail to the its Board of Directors, for a period of four years.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
May 16, 2017
Advent, Shanghai Pharma have not approached Stada – sources
German drug company Stada Arzneimittel AG has not been approached by Advent International or Shanghai Pharmaceuticals Holding with a counter offer, two sources close to the matter told Reuters on Monday.
May 15, 2017
US District Court upholds Horizon Pharma’s patent
The United States District Court for the District of New Jersey upheld the validity of Horizon Pharma’s patent covering Pennsaid (diclofenac sodium topical solution) 2% w/w, which Actavis Laboratories UT, Inc.(Actavis) has admitted that its proposed generic diclofenac sodium topical solution product would infringe.
May 15, 2017
Mereo BioPharma wraps up patients testing for its rare pulmonary disease drug
Mereo BioPharma Group, a clinical stage, biopharmaceutical company focused on rare and specialty diseases, has completed patient enrolment in the AETHER, multi-centre, double-blind, placebo-controlled Phase 2 dose-ranging study of acumapimod (BCT-197), for the treatment of patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
May 12, 2017
AstraZeneca’s cancer drug shows positive result in NSCLC treatment
AstraZeneca and its subsidiary MedImmune, have reported positive results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled multi-centre trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy.
May 11, 2017
Stada reports net income 33% up net income, recommends shareholders to accept takeover offer
Stada Arzneimittel has reported adjusted net income of €53.3 million for the first quarter of 2017 which is 33% increase compared to last years net income of €40.1 million.
May 11, 2017
Catalyst Pharmaceuticals reports $4.9M loss for Q1 2017
Catalyst Pharmaceuticals has reported a GAAP net loss of $4.9 million for first quarter of 2017, compared to a GAAP net loss of $5,4 for the same period in 2016.
May 10, 2017
Anavex Life Sciences reports $1.5M net loss for Q1 2017
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, todayhas reported financial results for the fiscal quarter ended March 31, 2017.
May 10, 2017
BMS and Calithera Biosciences expend collaboration to test its cancer drugs
Bristol-Myers Squibb (BMS) and Calithera Biosciences have expanded their existing collaboration to evaluate BMS’s Opdivo in combination with Calithera’s CB-839 in patients with non-small cell lung cancer (NSCLC) and melanoma.
May 10, 2017
Allergan proposes public offering of senior notes to refinance existing debt
Allergan announced that it expects to commence an offering of euro-denominated senior unsecured notes in multiple tranches in the coming weeks.